Posted: NOV 09, 2006

Frank D'Amelio Joins CSMG Technologies Live Tissue Connect Subsidiary as Consultant

Company Looks to Immediately Begin Regulatory Approval towards Product Commercialization

Corpus Christi, TX, November 09, 2006 -- CSMG Technologies, Inc., (OTC Bulletin Board: CTUM - News), a technology management, announced that Frank D'Amelio has joined its Live Tissue Connect ("LTC") technology subsidiary as a consultant to assist and advise the company in its goal to receive its first FDA regulatory approval and thereafter commercialize its tissue bonding product.

In our opinion Mr. D'Amelio has had a highly successful 24 year career with a major medical company and his accomplishments are internationally recognized in the medical device industry. Among his accomplishments are successfully launching more than 200 new medical device products including break through "industry first" technologies, directing production at five manufacturing facilities, sole or co-author of over 40 issued medical technology/products patents or patent pending applications world wide, helping lead numerous M&A deals valued between $3 million to $500 Million, contributing to FDA 510K and PMA filings and approvals, serving as lead executive for FDA inspections and deep experience in sales and marketing of new medical device products.

"Frank D'Amelio is, in our view, a seasoned medical device executive with a wealth of hands-on medical device development and management experience, a stellar performance record, a career that speaks for itself and a strong can-do attitude. We look forward to working with Frank as he begins to advise LTC through the regulatory, manufacturing, commercialization and marketing stages of a new medical product. We believe that we are fortunate to have Frank work with and advise LTC as a consultant." says Robbins.

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S. and Australia patents have been issued, a patent in the European Union has been approved, and additional U.S. and foreign patents are pending.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to http://www.ctum.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CSMG Technologies, Inc. - 500 No. Shoreline # 701 no. - Corpus Christi, TX 78471